Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

 
Phase: 1
Protocol No.Title
1999LS073MT1999-20 Hematopoietic cell transplantation in children with juvenile myelomonocytic leukemia
2011UC017OHSU BBBD (SOL-08131-L) Phase I/II Study of Intra-arterial Melphalan Given with Intra-arterial Carboplatin, Osmotic Blood-Brain Barrier Disruption and Delayed Otoprotective Sodium Thiosulfate for Patients with Recurrent or Progressive CNS Embryonal or Germ Cell Tumors
2013CG078COG ADVL1217: A PHASE 1 STUDY OF AZD1775 (MK-1775, IND# 116495) CONCURRENT WITH LOCAL RADIATION THERAPY FOR THE TREATMENT OF NEWLY DIAGNOSED CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMAS
2013LS081HM2013-24: Study of the ADAM17 Inhibitor INCB7839 Combined With Rituximab After Autologous Hematopoietic Cell Transplantation (HCT) For Patients With Diffuse Large B Cell Non-Hodgkin Lymphoma (DLBCL)
2014CG023COG ADVL1312 - A PHASE 1/2 STUDY OF AZD1775 (MK-1775 , IND# 121422) IN COMBINATION WITH ORAL IRINOTECAN IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY SOLID TUMORS
2014CG036COG ADVL1411 - A Phase 1/ 2 Study of BMN 673 (IND# 121510), an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children with Refractory or Recurrent Malignancies
2014CG076CITN-06:A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients with Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Squamous Cell Head and Neck Cancer
2014IS044Millenium C31001: A phase 1b/2 study of safety and efficacy of MLN0128 (Dual TORC 1/2 Inhibitor) in combination with exemestane or fulvestrant therapy in postmenopausal women with ER+/HER2- advanced or metastatic breast cancer that has progressed on treatment with everolimus in combination with exemestane or fulvestrant
2014IS062An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutation (MEK116540)
2014IS090APS001F-001 – A Phase I/II safety, pharmacokinetic, and pharmacodynamic study of APS001F with flucytosine and maltose for the treatment of advanced and/or metastatic solid tumors.
2014LS020MT2014-12:Phase I/II Study of Human Chorionic Gonadotropin and Epidermal Growth Factor Supplementation (Pregnyl®) to Support Tolerance and Repair As Adjunct Therapy in High-Risk or Refractory Acute Graft-Versus-Host Disease
2014LS093HM2014-26 DT2219 immunotoxin for the treatment of relapsed or refractory CD19 (+) and/or CD 22 (+) B-lineage leukemia or lymphoma
2015CG012COG ADVL1412 - A Phase 1/2 Study of Nivolumab (IND# 124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab Additional Title: ADVL1412-Bristol-Myers Squibb Company
2015CG028 GOG-286B A Randomized Phase I/II Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IV or Recurrent Endometrial Cancer
2015CG151ADVL1414 - A PHASE 1 STUDY OF SELINEXOR (KPT-330, IND #125052), A SELECTIVE XPO1 INHIBITOR, IN RECURRENT AND REFRACTORY PEDIATRIC SOLID TUMORS, INCLUDING CNS TUMORS
2015CG175COG ADVL1416 - A PHASE 1 STUDY OF RAMUCIRUMAB, A HUMAN MONOCLONAL ANTIBODY AGAINST THE VASCULAR ENDOTHELIAL GROWTH FACTOR-2 (VEGFR-2) RECEPTOR IN CHILDREN WITH REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS "ADVL1416 – Eli Lilly and Company"
2015IS075HM2015-18: A phase 1/2 study of ALT-803 in patients with relapse/refractory indolent B cell non-Hodgkin lymphoma in conjunction with rituximab
2015IS087A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally in Subjects with a Solid Tumor Cancer
2015IS104Pfizer A8081054: A Phase IB Study of Crizotinib in Combination with Pembrolizumab (MK-3475) in Patients with Untreated Advanced ALK-Translocated Non-Small Cell Lung Cancer
2016CG116COG ADVL1621 - A Phase I/II Study of Pembrolizumab (MK3475) in Children with advanced melanoma or a PDL1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE051) Additional Title: “ADVL1621 – Merck Sharp and Dohme Corp.”
2016CG156COG ADVL1513 - A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
2016IS002A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors (I5B-MC-JGDN)
2016IS005AN OPEN-LABEL, RANDOMIZED, ADAPTIVE, TWO-ARM, MULTICENTER TRIAL TO EVALUATE PHARMACOKINETICS AND PHARMACODYNAMICS OF TWO DOSES OF OSELTAMIVIR (TAMIFLU®) IN THE TREATMENT OF INFLUENZA IN IMMUNOCOMPROMISED CHILDREN LESS THAN 13 YEARS OF AGE, WITH CONFIRMED INFLUENZA INFECTION
2016IS013A Phase I/II Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer
2016IS044A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
2016IS065An open label, phase Ib, dose-escalation study evaluating the safety and tolerability of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours and in combination with endocrine therapy in patients with locally advanced or metastatic hormone receptor-positive, HER2-, breast cancer, followed by expansion cohorts
2016IS069A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects with Advanced Malignancies
2016IS140MT2016-36 A Phase I, Multicenter, Open-label, safety of Human Cord Blood Derived, Culture-Expanded, Natural Killer Cell (PNK-007) Infusion with subcutaneous Recombinant Human IL-2 (RHIL-2) following autologous stem cell transplant for Multiple Myeloma
2016LS034Randomized Study of Single Course of Intraperitoneal (IP) ALT-803 Followed by Subcutaneous (SQ) Maintenance ALT-803 Versus Subcutaneous (SQ) Maintenance ALT-803 Only after 1st Line Chemotherapy for Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
2016LS153MT2016-27 Open Label Dose Escalation Trial of an Adaptive Natural Killer (NK) Cell Infusion (FATE-NK100) with Subcutaneous IL-2 in Adults with Refractory or Relapsed Acute Myelogenous Leukemia (AML)
2016UC011A Phase IB/II study of nivolumab in combination with ALT-803 in patients with pretreated, advanced or metastatic non-small cell lung cancer
2017CG036COG ADVL1515 - A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors ADVL1515 - Eli Lilly and Company
2017CG088ADVL1514 - A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination With Temozolomide and Irinotecan
MT2009-09MT2009-09 Biochemical Correction of Severe Epidermolysis Bullosa by Allogeneic Stem Cell Transplantation
NEURO-2016-24616A Multicenter, Open-Label, Long-Term Treatment Study of Intravenously Administered BMS-986168 in Patients with Progressive Supranuclear Palsy Who Participated in Study CN002003
PEDS-2016-24779A Phase I, Multicenter, Open-label, Single-dose, Dose Ranging Study to Assess the Safety and Tolerability of SB-318, a rAAV2/6-based Gene Transfer in Subjects with Mucopolysaccharidosis I (MPS I)
PEDS-2017-25493EXTRA-CORPOREAL LIFE SUPPORT RESEARCH DATABASE
PSYCH-2016-18311Repetitive Transcranial Magnetic Stimulation for Adolescent Depression: Efficacy, Predictive Biomarkers and Mechanisms
PSYCH-2016-24867Disseminating and Implementing Empirically Supported Cognitive Behavioral Therapy (CBT) at Hazelden-Betty Ford Foundation
PSYCH-2016-24883Generalization of Conditioned Fear as a Pathogenic Marker of PTSD